Patents by Inventor Andrew A. Welcher

Andrew A. Welcher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATMENT USING AN INTERFERON GAMMA INHIBITOR
    Publication number: 20220144933
    Abstract: The invention encompasses methods of treatment of interferon gamma (IFN-?)-mediated diseases using IFN-? inhibitors, such as anti-huIFN-? antibodies, wherein levels of expression of one or more biomarkers are determined either before administration of the IFN-? inhibitor and/or after administration. Also contemplated are methods of treatment using particular, pharmacodynamically effective doses of an anti-huIFN-? antibody.
    Type: Application
    Filed: December 14, 2021
    Publication date: May 12, 2022
    Applicant: AMGEN INC.
    Inventors: Andrew A. WELCHER, Michael J. Boedigheimer, James B. Chung
  • Methods of treatment using an interferon gamma inhibitor
    Patent number: 11230597
    Abstract: The invention encompasses methods of treatment of interferon gamma (IFN-?)-mediated diseases using IFN-? inhibitors, such as anti-huIFN-? antibodies, wherein levels of expression of one or more biomarkers are determined either before administration of the IFN-? inhibitor and/or after administration. Also contemplated are methods of treatment using particular, pharmacodynamically effective doses of an anti-huIFN-? antibody.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: January 25, 2022
    Assignee: AMGEN INC.
    Inventors: Andrew A. Welcher, Michael J. Boedigheimer, James B. Chung
  • Assay for detecting TH1 and TH2 cell populations
    Patent number: 11156600
    Abstract: The present disclosure relates to a method for detecting T helper cell or CTL subpopulations in a subject affected by disease or disorder having an immune component. The methods are also useful for determining efficacy of a treatment of the disease or disorder by detecting skewing of the T helper cells and CTLs in a therapeutic or adverse direction.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: October 26, 2021
    Assignee: AMGEN INC.
    Inventors: Kevin Gorski, Jane R. Parnes, Jeannette Bigler, Michael J. Boedigheimer, Andrew A. Welcher
  • Assay for Detecting TH1 and TH2 Cell Populations
    Publication number: 20190219563
    Abstract: The present disclosure relates to a method for detecting T helper cell or CTL subpopulations in a subject affected by disease or disorder having an immune component. The methods are also useful for determining efficacy of a treatment of the disease or disorder by detecting skewing of the T helper cells and CTLs in a therapeutic or adverse direction.
    Type: Application
    Filed: December 17, 2018
    Publication date: July 18, 2019
    Inventors: Kevin Gorski, Jane R. Parnes, Jeannette Bigler, Michael J. Boedigheimer, Andrew A. Welcher
  • Assay for detecting Th1 and Th2 cell populations
    Patent number: 10156562
    Abstract: The present disclosure relates to a method for detecting T helper cell or CTL subpopulations in a subject affected by disease or disorder having an immune component. The methods are also useful for determining efficacy of a treatment of the disease or disorder by detecting skewing of the T helper cells and CTLs in a therapeutic or adverse direction.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: December 18, 2018
    Assignee: AMGEN INC.
    Inventors: Kevin Gorski, Jane R. Parnes, Jeannette Bigler, Michael J. Boedigheimer, Andrew A. Welcher
  • METHODS OF TREATMENT USING AN INTERFERON GAMMA INHIBITOR
    Publication number: 20180030132
    Abstract: The invention encompasses methods of treatment of interferon gamma (IFN-?)-mediated diseases using IFN-? inhibitors, such as anti-huIFN-? antibodies, wherein levels of expression of one or more biomarkers are determined either before administration of the IFN-? inhibitor and/or after administration. Also contemplated are methods of treatment using particular, pharmacodynamically effective doses of an anti-huIFN-? antibody.
    Type: Application
    Filed: August 31, 2017
    Publication date: February 1, 2018
    Applicant: AMGEN INC.
    Inventors: Andrew A. WELCHER, Michael J. BOEDIGHEIMER, James B. CHUNG
  • Assay for Detecting TH1 and TH2 Cell Populations
    Publication number: 20170082608
    Abstract: The present disclosure relates to a method for detecting T helper cell or CTL subpopulations in a subject affected by disease or disorder having an immune component. The methods are also useful for determining efficacy of a treatment of the disease or disorder by detecting skewing of the T helper cells and CTLs in a therapeutic or adverse direction.
    Type: Application
    Filed: May 15, 2015
    Publication date: March 23, 2017
    Inventors: Kevin Gorski, Jane R. Parnes, Jeanette Bigler, Michael J. Boedigheimer, Andrew A. Welcher
  • METHODS OF TREATMENT USING AN INTERFERON GAMMA INHIBITOR
    Publication number: 20160046709
    Abstract: The invention encompasses methods of treatment of interferon gamma (IFN-?)-mediated diseases using IFN-? inhibitors, such as anti-huIFN-? antibodies, wherein levels of expression of one or more biomarkers are determined either before administration of the IFN-? inhibitor and/or after administration. Also contemplated are methods of treatment using particular, pharmacodynamically effective doses of an anti-huIFN-? antibody.
    Type: Application
    Filed: September 22, 2015
    Publication date: February 18, 2016
    Applicant: AMGEN INC.
    Inventors: ANDREW A. WELCHER, MICHAEL J. BOEDIGHEIMER, JAMES B. CHUNG
  • Human anti-IFN-? neutralizing antibodies as selective IFN-? pathway inhibitors
    Patent number: 8906371
    Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: December 9, 2014
    Assignees: Amgen Inc., E.R. Squibb & Sons, L.L.C.
    Inventors: Andrew A. Welcher, Hilary T. Chute, Yue-Sheng Li, Haichun Huang
  • Human Anti-IFN-gamma Neutralizing Antibodies as Selective IFN-gamma Pathway Inhibitors
    Publication number: 20140004127
    Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
    Type: Application
    Filed: August 13, 2013
    Publication date: January 2, 2014
    Applicants: MEDAREX, INC., AMGEN INC.
    Inventors: Andrew A. Welcher, Hilary T. Chute, Yue-Sheng Li, Haichun Huang
  • Methods for treating IFN-? mediated diseases using human anti-IFN-? neutralizing antibodies as selective IFN-gamma pathway inhibitors
    Patent number: 8529893
    Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: September 10, 2013
    Assignees: Amgen Inc., Medarex, Inc.
    Inventors: Andrew A. Welcher, Hilary T. Chute, Yue-Sheng Li, Haichun Huang
  • METHODS OF TREATMENT USING AN IFN gamma INHIBITOR
    Publication number: 20130142809
    Abstract: The invention encompasses methods of treatment of interferon gamma (IFN-?)-mediated diseases using IFN-? inhibitors, such as anti-huIFN-? antibodies, wherein levels of expression of one or more biomarkers are determined either before administration of the IFN-? inhibitor and/or after administration. Also contemplated are methods of treatment using particular, pharmacodynamically effective doses of an anti-huIFN-? antibody.
    Type: Application
    Filed: November 21, 2012
    Publication date: June 6, 2013
    Inventors: Andrew A. Welcher, Michael J. Boedigheimer, James B. Chung
  • Human Anti-IFN-gamma Neutralizing Antibodies as Selective IFN-gamma Pathway Inhibitors
    Publication number: 20120269819
    Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
    Type: Application
    Filed: May 21, 2012
    Publication date: October 25, 2012
    Applicants: MEDAREX, INC., AMGEN INC.
    Inventors: Andrew A. Welcher, Hilary T. Chute, Yue-Sheng Luke Li, Haichun Huang
  • INTERFERON-LIKE PROTEINS AND USES THEREOF
    Publication number: 20120157666
    Abstract: The present invention provides Interferon-Like (IFN-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing IFN-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with IFN-L polypeptides.
    Type: Application
    Filed: February 14, 2012
    Publication date: June 21, 2012
    Inventors: ANDREW WELCHER, Duanzhi Wen, Michael Kelley
  • Nucleic acid molecules that encode human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitors
    Patent number: 8202976
    Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: June 19, 2012
    Assignees: Amgen Inc., Medarex, Inc.
    Inventors: Andrew A. Welcher, Hilary T. Chute, Yue-Sheng (Luke) Li, Haichun Huang
  • Interferon-like proteins and uses thereof
    Patent number: 8148109
    Abstract: The present invention provides Interferon-Like (IFN-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing IFN-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with IFN-L polypeptides.
    Type: Grant
    Filed: August 8, 2005
    Date of Patent: April 3, 2012
    Assignee: Amgen Inc.
    Inventors: Andrew Welcher, Duanzhi Wen, Michael Kelley
  • Human Anti-IFN-gamma Neutralizing Antibodies as Selective IFN-gamma Pathway Inhibitors
    Publication number: 20110045537
    Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
    Type: Application
    Filed: July 6, 2010
    Publication date: February 24, 2011
    Applicant: AMGEN INC.
    Inventors: Andrew A. Welcher, Hilary T. Chute, Yue-Sheng "Luke" Li, Haichun Huang
  • Interferon-like molecules and uses thereof
    Patent number: 7811791
    Abstract: The present invention provides Interferon-Like (IFN-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing IFN-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with IFN-L polypeptides.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: October 12, 2010
    Assignee: Amgen Inc.
    Inventors: Andrew Welcher, Duanzhi Wen, Michael Kelly
  • Human anti-IFN-? neutralizing antibodies as selective IFN-? pathway inhibitors
    Patent number: 7790859
    Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: September 7, 2010
    Assignee: Amgen Inc.
    Inventors: Andrew A. Welcher, Hilary T. Chute, Yue-Sheng Li, Haichun Huang
  • HUMAN ANTI-IFN-GAMMA NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-GAMMA PATHWAY INHIBITORS
    Publication number: 20080107655
    Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
    Type: Application
    Filed: December 21, 2007
    Publication date: May 8, 2008
    Applicants: Amgen Inc., Medarex, Inc.
    Inventors: Andrew Welcher, Hilary Chute, Yue-Sheng Li, Haichun Huang